170 related articles for article (PubMed ID: 37408806)
21. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
22. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
Gigante E; Ronot M; Bertin C; Ciolina M; Bouattour M; Dondero F; Cauchy F; Soubrane O; Vilgrain V; Paradis V
Liver Int; 2019 Dec; 39(12):2386-2396. PubMed ID: 31544304
[TBL] [Abstract][Full Text] [Related]
23. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
[TBL] [Abstract][Full Text] [Related]
24. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
[TBL] [Abstract][Full Text] [Related]
25. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
26. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
27. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
[TBL] [Abstract][Full Text] [Related]
28. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
[TBL] [Abstract][Full Text] [Related]
29. Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: A case series of four patients.
Ito T; Ishii T; Sumiyoshi S; Ogiso S; Fukumitsu K; Ito T; Yagi S; Seo S; Hata K; Taura K; Uemoto S
Int J Surg Case Rep; 2020; 74():46-52. PubMed ID: 32791447
[TBL] [Abstract][Full Text] [Related]
30. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
31. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021).
Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K
J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569
[TBL] [Abstract][Full Text] [Related]
32. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
[TBL] [Abstract][Full Text] [Related]
33. Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma.
Rhee H; Park JH; Park YN
J Liver Cancer; 2021 Mar; 21(1):12-24. PubMed ID: 37384273
[TBL] [Abstract][Full Text] [Related]
34. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.
Shen YT; Yue WW; Xu HX
Abdom Radiol (NY); 2023 Jun; 48(6):2019-2037. PubMed ID: 36961531
[TBL] [Abstract][Full Text] [Related]
37. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning?
Liu X; Khalvati F; Namdar K; Fischer S; Lewis S; Taouli B; Haider MA; Jhaveri KS
Eur Radiol; 2021 Jan; 31(1):244-255. PubMed ID: 32749585
[TBL] [Abstract][Full Text] [Related]
38. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.
Raevskaya O; Appelman H; Razumilava N
Curr Hepatol Rep; 2020 Dec; 19(4):478-485. PubMed ID: 33415066
[TBL] [Abstract][Full Text] [Related]
39. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
[TBL] [Abstract][Full Text] [Related]
40. CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma.
Wakizaka K; Yokoo H; Kamiyama T; Kakisaka T; Ohira M; Tani M; Kato K; Fujii Y; Sugiyama K; Nagatsu A; Shimada S; Orimo T; Kamachi H; Matsuoka R; Taketomi A
Hepatol Res; 2020 Feb; 50(2):258-267. PubMed ID: 31661725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
